Crossject announces significant improvement in Gaïa ESG rating
11 Septembre 2023 - 7:30AM
Press Release
Crossject announces
significant improvement in
Gaïa ESG rating
Scores 73/100, compared with 60 in 2022, with
improvements across all themes
Demonstrates Crossject’s commitment to
sustainability and responsible business practices
Dijon, France,
September 11, 2023, 7:30
CET – Crossject
(ISIN: FR0011716265; Euronext: ALCJ), a
specialty pharma company developing needle-free
autoinjectors for emergency
situations, announces a significant improvement in its ESG
(Environment, Social, Governance) Gaïa rating, achieving a score of
73/100. This compares with a rating of 60 last year and 46 in
2021.
Crossject’s Gaïa rating, compiled by EthiFinance
ESG Ratings, increased across all four themes, governance, social,
environment and external stakeholders. There were particularly
marked improvements in the ratings for environment and external
stakeholders' performance.
‘‘The significant step up in Crossject’s ESG
rating is material evidence of our commitment to sustainability and
responsible business practices across the entire company,”
said Patrick Alexandre, CEO of Crossject. “We have
adopted a proactive approach to achieve the best ESG standards,
embedding these in our broader strategy and operating performance,
and to document these through exhaustive reporting, including our
commitment to the chemical industry’s Responsible Care program. We
are proud to have received this recognition of our efforts and look
forward to continuing this strong progress.”
About EthiFinance ESG Ratings
Created in 2004, EthiFinance ESG Ratings
(formerly Gaïa Research) is the rating agency of the EthiFinance
group, dedicated to small and medium-sized companies listed on the
European stock markets. EthiFinance ESG Ratings offers, on a
subscription basis, access to ESG (Environment, Social, Governance)
data and scores on more than 2,300 listed companies in Europe,
including nearly 400 in France.
About Crossject
Crossject SA (Euronext:
ALCJ; www.crossject.com) is developing and will soon market a
portfolio of drugs for use in emergency situations (epilepsy,
overdose, allergic shock, severe migraine and asthma attack). With
its patented needle-free self-injection system, Crossject aims to
become the world leader in self-administered emergency medications.
The company has been listed on the Euronext Growth market in Paris
since 2014, and benefits from Bpifrance funding.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 (0)6 27 74
74 49sophie.baumont@cohesionbureau.com Buzz et
CompagnieChristelle Distinguin+33 (0)6 09 96 51
70christelle.distinguin@buzzetcompagnie.com |
|
- 2023-09-10 - Press release ESG_EN
Crossject (EU:ALCJ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Crossject (EU:ALCJ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024